Ratings of the last 12 months
This list shows every rating MEQIRI has published for a stock, an ETF or a coin, and every change between Strong, Neutral and Weak. For stocks it also shows every valuation signal and its changes.
Counted from the public launch on 7 Nov 2026.
- Price target: none, MEQIRI does not give price targets.
- Fair value: for the valuation signal, that day's fair value, converted like the price. An estimate from the disclosed model, not a price target.
- Validity: until the rating or the valuation signal changes, time horizon about 12 months, recalculated every night.
- Price: last close before publication, converted into dollars at that day's ECB rate; ETFs in euros.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
3 entries
- Cellebrite DI Ltd.13 Nov 2026Valuation signal Fairly valued (Before Overvalued), Fair value $5.54, $10.89
- Cellebrite DI Ltd.7 Nov 2026Neutral (first rating), Score 57, $12.45
- Cellebrite DI Ltd.7 Nov 2026Valuation signal Overvalued (first signal), Fair value $5.53, $12.45
| Date | Security | Rating | Before | Score | Fair value | Price |
|---|---|---|---|---|---|---|
| 13 Nov 2026 | Cellebrite DI Ltd. CLBT | Valuation signalFairly valued | Overvalued | $5.54 | $10.89 | |
| 7 Nov 2026 | Cellebrite DI Ltd. CLBT | Neutral | first rating | 57 | $12.45 | |
| 7 Nov 2026 | Cellebrite DI Ltd. CLBT | Valuation signalOvervalued | first signal | $5.53 | $12.45 |
Legal basis: Article 4(1)(i) of Delegated Regulation (EU) 2016/958.
To the disclosures